股本结构
单位：万股
| 公告日期 | 2024-04-01 | 2023-11-13 | 2023-11-13 | 2023-08-14 | 2023-08-14 | 2023-05-15 |
|---|---|---|---|---|---|---|
| 证券总股本 | 12530.41 | 12530.41 | 12530.40 | 12578.52 | 12650.50 | 12662.41 |
| 普通股本 | 12530.41 | 12530.41 | 12530.40 | 12578.52 | 12650.50 | 12662.41 |
| 优先股 | 0.06 | 未披露 | 0.10 | 未披露 | 0.10 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2023-12-31 | 2023-11-08 | 2023-09-30 | 2023-08-10 | 2023-06-30 | 2023-05-10 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2024-04-01 | 12530.41 | 0.06 |
更多>>
From December 31, 2022 to December 31, 2023
Common stock repurchased
|
2023-12-31 |
| 2023-11-13 | 12530.41 | 未披露 | 定期报告 | 2023-11-08 |
| 2023-11-13 | 12530.40 | 0.10 |
更多>>
From June 30, 2023 to September 30, 2023
Common stock repurchased
|
2023-09-30 |
| 2023-08-14 | 12578.52 | 未披露 | 定期报告 | 2023-08-10 |
| 2023-08-14 | 12650.50 | 0.10 |
更多>>
From March 31, 2023 to June 30, 2023
Common stock repurchased
|
2023-06-30 |
| 2023-05-15 | 12662.41 | 未披露 | 定期报告 | 2023-05-10 |
| 2023-05-15 | 12662.40 | 0.10 | 定期报告 | 2023-03-31 |
| 2023-03-22 | 12662.41 | 未披露 | 定期报告 | 2023-03-16 |
| 2023-03-22 | 12662.40 | 0.10 | 定期报告 | 2022-12-31 |
| 2022-11-07 | 12662.41 | 未披露 | 定期报告 | 2022-11-04 |
| 2022-11-07 | 12662.40 | 0.10 |
更多>>
From June 30, 2022 to September 30, 2022
Issuance of common stock upon warrant exercise
Conversion of Series B convertible preferred stock to common stock
Common stock issued for options exercises
Shares withheld related to cashless exercise of options and taxes
|
2022-09-30 |
| 2022-08-08 | 12662.41 | 未披露 | 定期报告 | 2022-08-05 |
| 2022-08-08 | 12662.40 | 0.10 | 定期报告 | 2022-06-30 |
| 2022-05-09 | 12662.41 | 未披露 | 定期报告 | 2022-05-06 |
| 2022-05-09 | 12662.40 | 0.10 | 定期报告 | 2022-03-31 |
| 2022-04-11 | 12678.95 | 未披露 | 定期报告 | 2022-03-25 |
| 2022-02-28 | 12662.41 | 未披露 | 定期报告 | 2022-02-18 |
| 2022-02-28 | 12662.40 | 0.10 |
更多>>
From December 31, 2020 to December 31, 2021
Issuance of common stock and warrants, net of issuance costs of $5,493
Issuance of common stock upon warrant exercise
Conversion of Series B convertible preferred stock to common stock
Common stock issued for option exercise
Shares withheld related to cashless exercise of options and taxes
Compensation cost for stock options granted
Cumulative effect of adopted accounting standard
|
2021-12-31 |
| 2021-11-15 | 12662.41 | 未披露 | 定期报告 | 2021-11-11 |
| 2021-11-15 | 12662.35 | 0.06 |
更多>>
From June 30, 2021 to September 30, 2021
Issuance of common stock upon warrant exercise
Conversion of Series B convertible preferred stock to common stock
Common stock issued for option exercise
Shares withheld related to cashless exercise of options and taxes
|
2021-09-30 |
| 2021-08-13 | 12662.33 | 未披露 | 定期报告 | 2021-08-06 |
| 2021-08-09 | 12643.58 | 未披露 | 定期报告 | 2021-07-22 |
| 2021-08-13 | 12592.51 | 0.06 |
更多>>
From March 31, 2021 to June 30, 2021
Conversion of Series B convertible preferred stock to common stock
Issuance of common stock upon warrant exercise
|
2021-06-30 |
| 2021-05-14 | 12082.44 | 0.06 |
更多>>
From December 31, 2020 to March 31, 2021
Conversion of Series B convertible preferred stock to common stock
Issuance of common stock and warrants, net of issuance costs of $5,493,310
Issuance of common stock upon warrant exercise
|
2021-03-31 |
| 2021-03-23 | 12082.44 | 未披露 |
更多>>
1.Common stock offered 17,361,100 shares.
2.The number of shares of common stock to be outstanding after this offering is based on 103,463,268 shares of common stock outstanding as of March 18, 2021.
|
2021-03-23 |
| 2021-03-23 | 10346.33 | 未披露 | 定期报告 | 2021-03-18 |
| 2021-01-22 | 7157.43 | 未披露 | 定期报告 | 2021-01-21 |
| 2021-01-08 | 7139.88 | 未披露 |
更多>>
1.Securities Offered Units consisting of an aggregate of 23,850,000 shares of common stock.
2.The number of shares of common stock to be outstanding after this offering is based on 47,548,835 shares of common stock outstanding as of January 5, 2021.
|
2021-01-08 |
| 2021-03-31 | 4754.88 | 0.06 |
更多>>
From December 31, 2019 to December 31, 2020
Issuance of common stock, net of issuance costs of $474,641
Issuance of common stock and warrants, net of issuance costs of $1,889,658
Conversion of Series B convertible preferred stock to common stock
Conversion of Series C convertible preferred stock to common stock
Common stock issued for option exercises
Shares withheld related to cashless exercise of options and taxes
Allocation of Series C convertible preferred stock to beneficial conversion feature and warrant liability
Deemed dividend on Series C convertible preferred stock
|
2020-12-31 |
| 2020-12-21 | 4387.38 | 未披露 |
更多>>
1.Common stock offered by the company 14,000,000 shares of common stock.
2.The number of shares of common stock to be outstanding after this offering is based on 29,873,835 shares of common stock outstanding as of December 16, 2020.
|
2020-12-21 |
| 2020-12-21 | 2987.38 | 未披露 | 定期报告 | 2020-12-16 |
| 2020-12-11 | 2503.93 | 未披露 |
更多>>
1.Securities Offered: Units consisting of an aggregate of 14,575,000 shares of our common stock.
2.The number of shares of common stock to be outstanding after this offering is based on 10,464,250 shares of common stock outstanding as of September 30, 2020.
|
2020-12-11 |
| 2020-11-13 | 1049.28 | 未披露 | 定期报告 | 2020-11-09 |
| 2020-11-13 | 1046.43 | 0.06 |
更多>>
From June 30, 2020 to September 30, 2020
Conversion of Series B convertible preferred stock to common stock
Issuance of common stock, net of issuance costs of $135,157
Common stock issued for option exercises
Shares withheld related to cashless exercise of options and taxes
|
2020-09-30 |
| 2020-08-13 | 1039.50 | 未披露 | 定期报告 | 2020-08-10 |
| 2020-08-13 | 930.39 | 0.06 |
更多>>
From March 31, 2020 to June 30, 2020
Issuance of common stock, net of issuance costs of $178,544
Conversion of Series B convertible preferred stock to common stock
|
2020-06-30 |
| 2020-05-13 | 920.85 | 未披露 | 定期报告 | 2020-05-08 |
| 2019-11-13 | 913.10 | 0.07 |
更多>>
From June 30, 2019 to September 30, 2019
Conversion of Series B convertible preferred stock to common stock
|
2019-09-30 |
| 2019-08-13 | 912.96 | 0.07 |
更多>>
From March 31, 2019 to June 30, 2019
Conversion of Series B convertible preferred stock to common stock
|
2019-06-30 |
| 2019-05-13 | 912.47 | 未披露 | 定期报告 | 2019-05-09 |
| 2019-04-12 | 912.44 | 未披露 | 定期报告 | 2019-04-11 |
| 2019-05-13 | 912.22 | 0.07 |
更多>>
From December 31, 2018 to March 31, 2019
Conversion of Series B convertible preferred stock to common stock
|
2019-03-31 |
| 2019-03-28 | 911.65 | 未披露 |
更多>>
In March 2019, the Company received approximately $11.3 million from exercises of warrants issued on May 30, 2018. As a result of the warrant exercises, the Company retired approximately 2.8 million warrants and issued approximately 2.8 million shares of common stock.
|
2019-03-25 |
| 2019-03-28 | 584.66 | 0.24 |
更多>>
From December 31, 2017 to December 31, 2018
Issuance of Series B convertible preferred stock, net of issuance costs of $1,333,449
Conversion of Series B convertible preferred stock to common stock
|
2018-12-31 |
| 2018-11-14 | 564.66 | 未披露 | 定期报告 | 2018-11-09 |
| 2018-11-14 | 552.33 | 0.35 |
更多>>
From December 31, 2017 to September 30, 2018
Issuance of Series B convertible preferred stock, net of issuance costs of $1,333,449
Conversion of Series B convertible preferred stock to common stock
|
2018-09-30 |
| 2018-08-13 | 506.96 | 未披露 | 定期报告 | 2018-08-10 |
| 2018-08-13 | 487.41 | 0.58 |
更多>>
From December 31, 2017 to June 30, 2018
Issuance of Series B convertible preferred stock, net of issuance costs of $1,333,449
Conversion of Series B convertible preferred stock to common stock
|
2018-06-30 |
| 2018-06-04 | 281.50 | 未披露 | 定期报告 | 2018-06-01 |
| 2018-05-03 | 265.20 | 未披露 | 定期报告 | 2018-05-02 |
| 2018-04-20 | 265.19 | 未披露 |
更多>>
Atossa Genetics Inc. today announced a reverse split of its common stock at a ratio of 1-for-12, effective April 20, 2018. The reverse split was approved by the Company's stockholders at an annual meeting of the stockholders initially held on April 12, 2018 and reconvened on April 19, 2018. The Company's common stock will continue to trade on the NASDAQ Capital Market under the trading symbol "ATOS."
|
2018-04-20 |
| 2018-05-14 | 265.20 | 未披露 | 定期报告 | 2018-03-31 |
| 2018-03-08 | 3182.27 | 未披露 |
更多>>
from December 31, 2016 to December 31, 2017
Issuance of Series A convertible preferred stock in Class B units, net of issuance costs of $267,231
Conversion of Series A convertible preferred stock to common stock
Issuance of common stock and warrants net of issuance costs of $768,412
Issuance of common stock in Class A units, net of issuance costs of $65,816
Reclassification of warrant liability upon exercise of common stock warrants
Issuance of common stock upon warrant exercise for cash on liability warrant exercise
|
2017-12-31 |
| 2017-11-13 | 2652.27 | 未披露 |
更多>>
On October 26, 2017, the Company entered into an underwriting agreement with Maxim Group LLC relating to a public offering of common stock which closed on October 30, 2017. The offering generated gross proceeds to the Company of approximately $5.5 million and net proceeds of $5.1 million after deducting underwriting discounts and commission.
The offering included 11,500,000 shares of common stock at a public offering price of $0.44 per share. In addition, the underwriter exercised the over-allotment to purchase an additional 1,000,000 shares of common stock, which are included in the estimated gross proceeds of $5.5 million.
|
2017-11-13 |
| 2017-11-13 | 1402.27 | 未披露 |
更多>>
from December 31, 2016 to September 30, 2017
Issuance of Series A convertible preferred stock in Class B units, net of issuance costs of $267,231
Conversion of Series A convertible preferred stock to common stock
Reclassification of warrant liability upon exercise of common stock warrants
Issuance of common stock upon warrant exercise for cash
|
2017-09-30 |
| 2017-08-14 | 1170.11 | 未披露 | 定期报告 | 2017-08-14 |
| 2017-08-14 | 1003.24 | 0.08 |
更多>>
from December 31, 2016 to June 30, 2017
Issuance of Series A convertible preferred stock in Class B units, net of issuance costs of $267,231
Conversion of Series A Convertible Preferred Stock to common stock
Issuance of common stock in Class A units, net of issuance costs of $65,816
Reclassification of warrant liability upon net cashless exercise of common stock warrants
Issuance of common stock upon warrant exercise for cash
|
2017-06-30 |
| 2017-05-11 | 741.29 | 未披露 | 定期报告 | 2017-05-10 |
| 2017-04-13 | 364.13 | 未披露 | 定期报告 | 2017-04-06 |
| 2017-03-16 | 378.69 | 未披露 |
更多>>
from December 31, 2015 to December 31, 2016
Issuance of common shares (net of issuance costs of $356,214)
Issuance of common shares as commitment fees
Settlement of fractional shares
On August 26, 2016, the Company completed a 1-for-15 reverse stock split of the shares of the Company’s common stock (the “Reverse Stock Split”).
|
2016-12-31 |
| 2016-11-14 | 378.80 | 未披露 |
更多>>
from December 31, 2015 to September 30, 2016
Issuance of common shares and warrants (net of issuance costs of $356,214)
Issuance of common shares as commitment fees
Atossa Genetics Inc. today announced a reverse split of its common stock at a ratio of 1-for-15, effective August 26, 2016, and that the Company's common stock will begin trading on a split-adjusted basis when the market opens on August 26, 2016.
|
2016-09-30 |
| 2016-08-25 | 263.80 | 未披露 |
更多>>
Atossa Genetics Inc. today announced a reverse split of its common stock at a ratio of 1-for-15, effective August 26, 2016, and that the Company's common stock will begin trading on a split-adjusted basis when the market opens on August 26, 2016.
|
2016-08-26 |
| 2016-08-12 | 3956.95 | 未披露 |
更多>>
from December 31, 2015 to June 30, 2016
Issuance of common shares and warrants (net of issuance costs of $43,110)
Issuance of common shares as commitment fees
|
2016-06-30 |
| 2016-06-03 | 3956.95 | 未披露 | 定期报告 | 2016-05-25 |
| 2016-05-05 | 3882.35 | 未披露 | 定期报告 | 2016-03-31 |
| 2016-03-30 | 3882.35 | 未披露 |
更多>>
In 2016 through the date of filing this report, we have sold 6,086,207 shares of common stock to Aspire under the November 11, 2015 agreement with them for aggregate gross proceeds to us of $2,153,583.
|
2016-03-28 |
| 2016-03-30 | 3265.73 | 未披露 |
更多>>
from December 31, 2014 to December 31, 2015
Issuance of common shares and warrants (net of issuance costs of $1,011,574)
|
2015-12-31 |
| 2015-11-12 | 3044.63 | 未披露 |
更多>>
In June 2015, we sold 1,454,003 shares of common stock at the purchase price of $1.15 per share and pre-funded warrants to purchase 3,610,997 shares of common stock (the “Pre-Funded Warrants”) at a purchase price of $1.14 per share for total gross proceeds of $5.8 million (the “2015 Offering”).
|
2015-09-30 |
| 2015-08-06 | 2904.63 | 未披露 |
更多>>
from December 31, 2014 to June 30, 2015
Issuance of common shares for cash
Deferred financing costs net of amortization
|
2015-06-30 |
| 2015-06-26 | 2904.63 | 未披露 | 定期报告 | 2015-06-05 |
| 2015-05-13 | 2721.73 | 未披露 |
更多>>
from December 31, 2014 to March 31, 2015
Issuance of common shares for cash
|
2015-03-31 |
| 2015-03-30 | 2539.61 | 未披露 | 定期报告 | 2015-03-27 |
| 2014-11-12 | 2456.41 | 未披露 |
更多>>
From December 31, 2013 to September 30, 2014
Issuance of common shares for cash
Issuance of common shares for services
Issuance of Common shares upon exercise of warrants
Employees option exercise and cancellation of restricted stock grants
|
2014-09-30 |
| 2014-08-12 | 2456.41 | 未披露 | 定期报告 | 2014-08-12 |
| 2014-08-12 | 2444.41 | 未披露 |
更多>>
From December 31, 2013 to June 30, 2014
Issuance of common shares for cash
Issuance of common shares for services
Issuance of Common shares upon exercise of warrants
Employees option exercise and cancellation of restricted stock grants
|
2014-06-30 |
| 2014-05-14 | 2442.86 | 未披露 | 定期报告 | 2014-03-31 |
| 2014-03-27 | 2442.86 | 未披露 | 定期报告 | 2014-03-24 |
| 2014-03-27 | 1857.43 | 未披露 |
更多>>
From December 31,2012 to December 31,2013
Issuance of common shares for cash
Issuance of common shares for services
Issuance of common shares for capital raising fees , net
Issuance of Common shares for warrants
Issuance of Common shares for exercise employees options
|
2013-12-31 |
| 2013-11-12 | 1802.48 | 未披露 | 定期报告 | 2013-11-08 |
| 2013-11-12 | 1744.48 | 未披露 | 定期报告 | 2013-09-30 |
| 2013-08-14 | 1558.01 | 未披露 | 定期报告 | 2013-08-09 |
| 2013-08-14 | 1533.81 | 未披露 | 定期报告 | 2013-06-30 |
| 2013-05-15 | 1467.72 | 未披露 | 定期报告 | 2013-05-10 |
| 2013-04-15 | 1454.26 | 未披露 | 定期报告 | 2013-04-05 |
| 2013-05-15 | 1450.80 | 未披露 | 定期报告 | 2013-03-31 |
| 2013-03-28 | 1417.47 | 未披露 | 定期报告 | 2013-03-27 |
| 2013-03-28 | 1291.94 | 未披露 |
更多>>
from December 31, 2011 to December 31, 2012
Issuance of common shares for cash
Issuance of common shares for cash and asset purchase
|
2012-12-31 |
| 2012-11-07 | 1291.94 | 未披露 | 定期报告 | 2012-11-08 |
| 2012-12-21 | 1211.94 | 未披露 | 定期报告 | 2012-09-30 |
| 2012-06-18 | 1125.69 | 未披露 | 定期报告 | 2012-03-31 |
From December 31, 2022 to December 31, 2023
Common stock repurchased
From June 30, 2023 to September 30, 2023
Common stock repurchased
From March 31, 2023 to June 30, 2023
Common stock repurchased
From June 30, 2022 to September 30, 2022
Issuance of common stock upon warrant exercise
Conversion of Series B convertible preferred stock to common stock
Common stock issued for options exercises
Shares withheld related to cashless exercise of options and taxes
From December 31, 2020 to December 31, 2021
Issuance of common stock and warrants, net of issuance costs of $5,493
Issuance of common stock upon warrant exercise
Conversion of Series B convertible preferred stock to common stock
Common stock issued for option exercise
Shares withheld related to cashless exercise of options and taxes
Compensation cost for stock options granted
Cumulative effect of adopted accounting standard
From June 30, 2021 to September 30, 2021
Issuance of common stock upon warrant exercise
Conversion of Series B convertible preferred stock to common stock
Common stock issued for option exercise
Shares withheld related to cashless exercise of options and taxes
From March 31, 2021 to June 30, 2021
Conversion of Series B convertible preferred stock to common stock
Issuance of common stock upon warrant exercise
From December 31, 2020 to March 31, 2021
Conversion of Series B convertible preferred stock to common stock
Issuance of common stock and warrants, net of issuance costs of $5,493,310
Issuance of common stock upon warrant exercise
1.Common stock offered 17,361,100 shares.
2.The number of shares of common stock to be outstanding after this offering is based on 103,463,268 shares of common stock outstanding as of March 18, 2021.
1.Securities Offered Units consisting of an aggregate of 23,850,000 shares of common stock.
2.The number of shares of common stock to be outstanding after this offering is based on 47,548,835 shares of common stock outstanding as of January 5, 2021.
From December 31, 2019 to December 31, 2020
Issuance of common stock, net of issuance costs of $474,641
Issuance of common stock and warrants, net of issuance costs of $1,889,658
Conversion of Series B convertible preferred stock to common stock
Conversion of Series C convertible preferred stock to common stock
Common stock issued for option exercises
Shares withheld related to cashless exercise of options and taxes
Allocation of Series C convertible preferred stock to beneficial conversion feature and warrant liability
Deemed dividend on Series C convertible preferred stock
1.Common stock offered by the company 14,000,000 shares of common stock.
2.The number of shares of common stock to be outstanding after this offering is based on 29,873,835 shares of common stock outstanding as of December 16, 2020.
1.Securities Offered: Units consisting of an aggregate of 14,575,000 shares of our common stock.
2.The number of shares of common stock to be outstanding after this offering is based on 10,464,250 shares of common stock outstanding as of September 30, 2020.
From June 30, 2020 to September 30, 2020
Conversion of Series B convertible preferred stock to common stock
Issuance of common stock, net of issuance costs of $135,157
Common stock issued for option exercises
Shares withheld related to cashless exercise of options and taxes
From March 31, 2020 to June 30, 2020
Issuance of common stock, net of issuance costs of $178,544
Conversion of Series B convertible preferred stock to common stock
From June 30, 2019 to September 30, 2019
Conversion of Series B convertible preferred stock to common stock
From March 31, 2019 to June 30, 2019
Conversion of Series B convertible preferred stock to common stock
From December 31, 2018 to March 31, 2019
Conversion of Series B convertible preferred stock to common stock
In March 2019, the Company received approximately $11.3 million from exercises of warrants issued on May 30, 2018. As a result of the warrant exercises, the Company retired approximately 2.8 million warrants and issued approximately 2.8 million shares of common stock.
From December 31, 2017 to December 31, 2018
Issuance of Series B convertible preferred stock, net of issuance costs of $1,333,449
Conversion of Series B convertible preferred stock to common stock
From December 31, 2017 to September 30, 2018
Issuance of Series B convertible preferred stock, net of issuance costs of $1,333,449
Conversion of Series B convertible preferred stock to common stock
From December 31, 2017 to June 30, 2018
Issuance of Series B convertible preferred stock, net of issuance costs of $1,333,449
Conversion of Series B convertible preferred stock to common stock
Atossa Genetics Inc. today announced a reverse split of its common stock at a ratio of 1-for-12, effective April 20, 2018. The reverse split was approved by the Company's stockholders at an annual meeting of the stockholders initially held on April 12, 2018 and reconvened on April 19, 2018. The Company's common stock will continue to trade on the NASDAQ Capital Market under the trading symbol "ATOS."
from December 31, 2016 to December 31, 2017
Issuance of Series A convertible preferred stock in Class B units, net of issuance costs of $267,231
Conversion of Series A convertible preferred stock to common stock
Issuance of common stock and warrants net of issuance costs of $768,412
Issuance of common stock in Class A units, net of issuance costs of $65,816
Reclassification of warrant liability upon exercise of common stock warrants
Issuance of common stock upon warrant exercise for cash on liability warrant exercise
On October 26, 2017, the Company entered into an underwriting agreement with Maxim Group LLC relating to a public offering of common stock which closed on October 30, 2017. The offering generated gross proceeds to the Company of approximately $5.5 million and net proceeds of $5.1 million after deducting underwriting discounts and commission.
The offering included 11,500,000 shares of common stock at a public offering price of $0.44 per share. In addition, the underwriter exercised the over-allotment to purchase an additional 1,000,000 shares of common stock, which are included in the estimated gross proceeds of $5.5 million.
from December 31, 2016 to September 30, 2017
Issuance of Series A convertible preferred stock in Class B units, net of issuance costs of $267,231
Conversion of Series A convertible preferred stock to common stock
Reclassification of warrant liability upon exercise of common stock warrants
Issuance of common stock upon warrant exercise for cash
from December 31, 2016 to June 30, 2017
Issuance of Series A convertible preferred stock in Class B units, net of issuance costs of $267,231
Conversion of Series A Convertible Preferred Stock to common stock
Issuance of common stock in Class A units, net of issuance costs of $65,816
Reclassification of warrant liability upon net cashless exercise of common stock warrants
Issuance of common stock upon warrant exercise for cash
from December 31, 2015 to December 31, 2016
Issuance of common shares (net of issuance costs of $356,214)
Issuance of common shares as commitment fees
Settlement of fractional shares
On August 26, 2016, the Company completed a 1-for-15 reverse stock split of the shares of the Company’s common stock (the “Reverse Stock Split”).
from December 31, 2015 to September 30, 2016
Issuance of common shares and warrants (net of issuance costs of $356,214)
Issuance of common shares as commitment fees
Atossa Genetics Inc. today announced a reverse split of its common stock at a ratio of 1-for-15, effective August 26, 2016, and that the Company's common stock will begin trading on a split-adjusted basis when the market opens on August 26, 2016.
Atossa Genetics Inc. today announced a reverse split of its common stock at a ratio of 1-for-15, effective August 26, 2016, and that the Company's common stock will begin trading on a split-adjusted basis when the market opens on August 26, 2016.
from December 31, 2015 to June 30, 2016
Issuance of common shares and warrants (net of issuance costs of $43,110)
Issuance of common shares as commitment fees
In 2016 through the date of filing this report, we have sold 6,086,207 shares of common stock to Aspire under the November 11, 2015 agreement with them for aggregate gross proceeds to us of $2,153,583.
from December 31, 2014 to December 31, 2015
Issuance of common shares and warrants (net of issuance costs of $1,011,574)
In June 2015, we sold 1,454,003 shares of common stock at the purchase price of $1.15 per share and pre-funded warrants to purchase 3,610,997 shares of common stock (the “Pre-Funded Warrants”) at a purchase price of $1.14 per share for total gross proceeds of $5.8 million (the “2015 Offering”).
from December 31, 2014 to June 30, 2015
Issuance of common shares for cash
Deferred financing costs net of amortization
from December 31, 2014 to March 31, 2015
Issuance of common shares for cash
From December 31, 2013 to September 30, 2014
Issuance of common shares for cash
Issuance of common shares for services
Issuance of Common shares upon exercise of warrants
Employees option exercise and cancellation of restricted stock grants
From December 31, 2013 to June 30, 2014
Issuance of common shares for cash
Issuance of common shares for services
Issuance of Common shares upon exercise of warrants
Employees option exercise and cancellation of restricted stock grants
From December 31,2012 to December 31,2013
Issuance of common shares for cash
Issuance of common shares for services
Issuance of common shares for capital raising fees , net
Issuance of Common shares for warrants
Issuance of Common shares for exercise employees options
from December 31, 2011 to December 31, 2012
Issuance of common shares for cash
Issuance of common shares for cash and asset purchase